source
- Lilly reports early positive results for new JAK2 inhibitor in hard-to-treat myelofibrosisLilly has incorporated a JAK2‑targeting drug originally discovered by Ajax Therapeutics after its recent acquisition. The experimental pill is intended for patients with myelofibrosis, a difficult‑…
- Sanofi’s Tzield approved amid review dispute as Bicillin shortage hampers syphilis treatmentAn Arizona woman pregnant with syphilis could not receive timely treatment because of a worsening shortage of Bicillin, the injectable penicillin made by Pfizer. The shortage has raised concerns ab…